Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial

Cited in:

CrossRef

This article has been cited by:

1. 1
   Mina Nakagawa, Naoya Sakamoto, Takako Watanabe, Yuki Nishimura-Sakurai, Izumi Onozuka, Seishin Azuma, Sei Kakinuma, Sayuri Nitta, Kei Kiyohashi, Akiko Kusano-Kitazume, Miyako Murakawa, Kohei Yoshino, Yasuhiro Itsui, Yasuhito Tanaka, Masashi Mizokami, Mamoru Watanabe, Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C, Hepatology International, 2012,

   CrossRef

2. 2
   Virginia Clark, David R. Nelson, The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C, Liver International, 2012, 32,

   Direct Link:

   • Abstract
   • Full Article (HTML)
   • PDF(282K)
   • References
3. 3
   Ajit Sood, Praveen Sobti, Vandana Midha, Dinesh Singla, Amarjeet Kaur, Sandeep Kaushal, Neena Sood, Rasham Mittal, Sandeep Puri, Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C, Indian Journal of Gastroenterology, 2011, 29, 2, 62

   CrossRef

4. 4
   Stefan Zeuzem, Tarik Asselah, Peter Angus, Jean–Pierre Zarski, Dominique Larrey, Beat Müllhaupt, Ed Gane, Marcus Schuchmann, Ansgar Lohse, Stanislas Pol, Jean–Pierre Bronowicki, Stuart Roberts, Keikawus Arasteh, Fabien Zoulim, Markus Heim, Jerry O. Stern, George Kukolj, Gerhard Nehmiz, Carla Haefner, Wulf Otto Boecher, Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection, Gastroenterology, 2011, 141, 6, 2047

   CrossRef

5. 5
   Peter A. Hevezi, Edward Tom, Keith Wilson, Peter Lambert, Gabriela Gutierrez-Reyes, David Kershenobich, Albert Zlotnik, Gene expression patterns in livers of Hispanic patients infected with hepatitis C virus, Autoimmunity, 2011, 44, 7, 532

   CrossRef

6. 6
   Christopher P Farrell, Giancarlo Mercogliano, Victor J Navarro, Simona Rossi, Taribavirin: potential future in the treatment of hepatitis C, Future Virology, 2011, 6, 2, 147

   CrossRef

7. 7
   Elisabetta Cariani, Erica Villa, Cristina Rota, Rosina Critelli, Tommaso Trenti, Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection, Clinical Chemistry and Laboratory Medicine, 2011, 1247

   CrossRef

8. 8
   Michael McDowell, Sarah R. Gonzales, Sidath C. Kumarapperuma, Marjan Jeselnik, Jeffrey B. Arterburn, Kathryn A. Hanley, A novel nucleoside analog, 1-β-d-ribofuranosyl-3-ethynyl-[1,2,4]triazole (ETAR), exhibits efficacy against a broad range of flaviviruses in vitro, Antiviral Research, 2010, 87, 1, 78

   CrossRef

9. 9
   Chun-Hao Chen, Ming-Lung Yu, Evolution of Interferon-Based Therapy for Chronic Hepatitis C, Hepatitis Research and Treatment, 2010, 2010, 1

   CrossRef

10. 10
    Naoya Sakamoto, Yasuhito Tanaka, Mina Nakagawa, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Nobuyuki Enomoto, Seishin Azuma, Yuki Nishimura-Sakurai, Sei Kakinuma, Nao Nishida, Katsushi Tokunaga, Masao Honda, Kiyoaki Ito, Masashi Mizokami, Mamoru Watanabe, ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C, Hepatology Research, 2010, 40, 11

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(233K)
    • References
11. 11
    Christian Trepo, Francois Bailly, Maintenance ribavirin monotherapy: The case for post-transplantation recurrent hepatitis C, Digestive and Liver Disease, 2010, 42, 4, 283

    CrossRef

12. 12
    François Bailly, Si Nafa Si Ahmed, Pierre Pradat, Christian Trepo, Management of nonresponsive hepatitis C, Expert Review of Anti-infective Therapy, 2010, 8, 4, 379

    CrossRef

13. 13
    Mamta K Jain, Cindy Zoellner, Role of ribavirin in HCV treatment response: now and in the future, Expert Opinion on Pharmacotherapy, 2010, 11, 4, 673

    CrossRef

14. 14
    Patrick Marcellin, Robert G. Gish, Norman Gitlin, Jamie Heise, Deanine G. Halliman, Eric Chun, Maribel Rodriguez-Torres, Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients, Journal of Hepatology, 2010, 52, 1, 32

    CrossRef

15. 15
    Lotte G. Van Vlerken, Hanneke Van Soest, Mart P. Janssen, Greet J. Boland, Joost P.H. Drenth, David M. Burger, Peter D. Siersema, Karel J. Van Erpecum, Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment, European Journal of Gastroenterology & Hepatology, 2010, 22, 11, 1308

    CrossRef

16. 16
    Myra Sgorbini, Louise O’Brien, Debra Jackson, Living with hepatitis C and treatment: the personal experiences of patients, Journal of Clinical Nursing, 2009, 18, 16

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(95K)
    • References
17. 17
    Kuo-Chih Tseng, Li-Hsuan Chen, Chi-Yi Chen, Ting-Tsung Chang, An-Liang Chou, I-Chin Wu, Pin-Nan Cheng, Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b, Hepatology Research, 2009, 39, 6

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(191K)
    • References
18. 18
    Alessio Aghemo, Maria Grazia Rumi, Massimo Colombo, Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C, Expert Review of Anti-infective Therapy, 2009, 7, 8, 925

    CrossRef

19. 19
    K. Rajender Reddy, David R. Nelson, Stefan Zeuzem, Ribavirin: Current role in the optimal clinical management of chronic hepatitis C, Journal of Hepatology, 2009, 50, 2, 402

    CrossRef

20. 20
    Tomoko Fujimoto, Masahiko Tomimatsu, Daijiro Iga, Hitoshi Endo, Kuniaki Otsuka, Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 8pt2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(277K)
    • References
21. 21
    Naoki Hiramatsu, Nao Kurashige, Tsugiko Oze, Tetsuo Takehara, Shinji Tamura, Akinori Kasahara, Masahide Oshita, Kazuhiro Katayama, Harumasa Yoshihara, Yasuharu Imai, Michio Kato, Sumio Kawata, Hirohito Tsubouchi, Hiromitsu Kumada, Takeshi Okanoue, Shinichi Kakumu, Norio Hayashi, Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C, Hepatology Research, 2008, 38, 1

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(237K)
    • References
22. 22
    Vincent Lo Re, Jay R. Kostman, Valerianna K. Amorosa, Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century, Clinics in Liver Disease, 2008, 12, 3, 587

    CrossRef

23. 23
    Mitchell L. Shiffman, Optimizing the Current Therapy for Chronic Hepatitis C Virus: Peginterferon and Ribavirin Dosing and the Utility of Growth Factors, Clinics in Liver Disease, 2008, 12, 3, 487

    CrossRef

24. 24
    Paul Martin, Donald M Jensen, Ribavirin in the treatment of chronic hepatitis C, Journal of Gastroenterology and Hepatology, 2008, 23, 6

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(356K)
    • References
25. 25
    Keith R Kearney, James J Thornton, Victor J Navarro, Taribavirin for the treatment of chronic hepatitis C, Expert Opinion on Pharmacotherapy, 2008, 9, 18, 3243

    CrossRef

26. 26
    Yves Benhamou, Anemia and clinical outcomes in hepatitis C, Journal of Hepatology, 2007, 47, 1, 7

    CrossRef

27. 27
    Sammy Saab, Mina K. Oh, Ayman B. Ibrahim, Francisco Durazo, Steven Han, Hasan Yersiz, Douglas G. Farmer, R. Mark Ghobrial, Leonard I. Goldstein, Myron J. Tong, Ronald W. Busuttil, Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C, Liver Transplantation, 2007, 13, 7

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(166K)
    • References
28. 28
    K. Rajender Reddy, Mitchell L. Shiffman, Timothy R. Morgan, Stefan Zeuzem, Stephanos Hadziyannis, Fayez M. Hamzeh, Teresa L. Wright, Michael Fried, Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment, Clinical Gastroenterology and Hepatology, 2007, 5, 1, 124

    CrossRef

29. 29
    Graham S Cooke, Janice Main, Improving the treatment of hepatitis C infection in the UK, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 183

    CrossRef

30. 30
    Lucas C. Quarantini, Rodrigo A. Bressan, Amanda Galvão, Susana Batista-Neves, Raymundo Paraná, Ângela Miranda-Scippa, Incidence of psychiatric side effects during pegylated interferon- α retreatment in nonresponder hepatitis C virus-infected patients, Liver International, 2007, 27, 8

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(77K)
    • References
31. 31
    Glen Lutchman, Susan Danehower, Byung–Cheol Song, T. Jake Liang, Jay H. Hoofnagle, Michael Thomson, Marc G. Ghany, Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy, Gastroenterology, 2007, 132, 5, 1757

    CrossRef

32. 32
    David H. Henry, Jihad Slim, Anthony Lamarca, Peter Bowers, Gerhard Leitz, Natural History of Anemia Associated with Interferon/Ribavirin Therapy for Patients with HIV/HCV Coinfection, AIDS Research and Human Retroviruses, 2007, 23, 1, 1

    CrossRef

33. 33
    Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, John G. McHutchison, Robert G. Gish, Nezam H. Afdhal, Manana Makhviladze, Mira Huyghe, David Hecht, Tilman Oltersdorf, David A. Shapiro, Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C, Hepatology, 2007, 46, 2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(821K)
    • References
34. 34
    Robert G. Gish, Sanjeev Arora, K. Rajender Reddy, David R. Nelson, Christopher O’Brien, Yi Xu, Brian Murphy, Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study, Journal of Hepatology, 2007, 47, 1, 51

    CrossRef

35. 35
    Eduardo Vilar Gomez, Bienvenido Gra Oramas, Enrique Arus Soler, Raimundo Llanio Navarro, Caridad Ruenes Domech, Viusid, a nutritional supplement, in combination with interferon α-2b and ribavirin in patients with chronic hepatitis C, Liver International, 2007, 27, 2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(159K)
    • References
36. 36
    Norio Hayashi, Tetsuo Takehara, Antiviral therapy for chronic hepatitis C: past, present, and future, Journal of Gastroenterology, 2006, 41, 1, 17

    CrossRef

37. 37
    Sangik Oh, Nezam H. Afdhal, Antiviral Therapy for Treatment Naïve Patients with Hepatitis C Virus, Infectious Disease Clinics of North America, 2006, 20, 1, 99

    CrossRef

38. 38
    C. Bradley Hare, Jonathan A. Morris, Alice Chu, Vincent Gotz, Jacqueline J. Loveland, David Hodes, Winslow Klaskala, Comparison of characteristics of treated and non-treated patients with Hepatitis C infection, Pharmacoepidemiology and Drug Safety, 2006, 15, 2

    Direct Link:

    • Abstract
    • PDF(81K)
    • References
39. 39
    Tsugiko Oze, Naoki Hiramatsu, Nao Kurashige, Natsuko Tsuda, Takayuki Yakushijin, Tatsuya Kanto, Tetsuo Takehara, Akinori Kasahara, Michio Kato, Harumasa Yoshihara, Kazuhiro Katayama, Shinji Kubota, Taizo Hijioka, Kazunobu Ishibashi, Masahide Oshita, Hideki Hagiwara, Yoshimichi Haruna, Eiji Mita, Shinji Tamura, Norio Hayashi, Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C, Journal of Gastroenterology, 2006, 41, 9, 862

    CrossRef

40. 40
    R. S. Brown, Evaluating the evidence from clinical trials in chronic hepatitis C, Journal of Viral Hepatitis, 2006, 13,

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(142K)
    • References
41. 41
    N. Fujita, M. Kaito, H. Tanaka, S. Horiike, N. Urawa, R. Sugimoto, M. Konishi, S. Watanabe, Y. Adachi, Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients, Journal of Viral Hepatitis, 2006, 13, 3

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(230K)
    • References
42. 42
    Gregory M. Asnis, Richard De La Garza, Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches, Journal of Clinical Gastroenterology, 2006, 40, 4, 322

    CrossRef

43. 43
    Jason D. Graci, Craig E. Cameron, Mechanisms of action of ribavirin against distinct viruses, Reviews in Medical Virology, 2006, 16, 1

    Direct Link:

    • Abstract
    • PDF(184K)
    • References
44. 44
    Josef Donnerer, Maja Grahovic, Evelyn Stelzl, Harald H. Kessler, Csilla Bankuti, Vanessa Stadlbauer, Rudolf E. Stauber, Ribavirin Levels and Haemoglobin Decline in Early Virological Responders and Non-Responders to Hepatitis C Virus Combination Therapy, Pharmacology, 2006, 76, 3, 136

    CrossRef

45. 45
    Jesper Brok, Lise L. Gluud, Christian Gluud, Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials, The American Journal of Gastroenterology, 2006, 101, 4, 842

    CrossRef

46. 46
    C.-W. Tsao, Y.-S. Lin, J.-T. Cheng, W.-W. Chang, C.-L. Chen, S.-R. Wu, C.-W. Fan, H.-Y. Lo, Serotonin Transporter mRNA Expression is Decreased by Lamivudine and Ribavirin and Increased by Interferon in Immune Cells, Scandinavian Journal of Immunology, 2006, 63, 2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(330K)
    • References
47. 47
    Thierry Thevenot, Vincent Di Martino, Françoise Lunel-Fabiani, Claire Vanlemmens, Marie-Claude Becker, Jean-Pierre Bronowicki, Solange Bresson-Hadni, Jean-Philippe Miguet, Traitements complémentaires de l’hépatite chronique virale C, Gastroentérologie Clinique et Biologique, 2006, 30, 2, 197

    CrossRef

48. 48
    Rise Stribling, Norman Sussman, John M. Vierling, Treatment of Hepatitis C Infection, Gastroenterology Clinics of North America, 2006, 35, 2, 463

    CrossRef

49. 49
    Furqaan Ahmed, Ira M. Jacobson, Treatment of Relapsers after Combination Therapy for Chronic Hepatitis C, Infectious Disease Clinics of North America, 2006, 20, 1, 137

    CrossRef

50. 50
    Keiichi Fujiwara, Osamu Yokosuka, Fumihiko Komine, Mitsuhiko Moriyama, Naoya Kato, Haruhiko Yoshida, Naohide Tanaka, Fumio Imazeki, Yasushi Shiratori, Yasuyuki Arakawa, Masao Omata, Twenty-four weeks of interferon α-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1, Liver International, 2006, 26, 5

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(134K)
    • References
51. 51
    Mitchell L. Shiffman, Vinod K. Rustgi, Use of Ribavirin in Patients With Chronic HCV Genotype 1: When Enough Is Really Enough, Gastroenterology, 2006, 131, 4, 1339

    CrossRef

52. 52
    Jennifer E. Layden-Almer, Scott J. Cotler, Thomas J. Layden, Viral kinetics in the treatment of chronic hepatitis C, Journal of Viral Hepatitis, 2006, 13, 8

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(149K)
    • References
53. 53
    R. Todd Stravitz, Harold Chung, Richard K. Sterling, Velimir A. Luketic, Arun J. Sanyal, Angie S. Price, Amy Purrington, Mitchell L. Shiffman, Antibody-Mediated Pure Red Cell Aplasia Due to Epoetin Alfa During Antiviral Therapy of Chronic Hepatitis C, The American Journal of Gastroenterology, 2005, 100, 6, 1415

    CrossRef

54. 54
    C. Bradley Hare, Jacqueline J. Loveland, Alice Chu, Jonathan A. Morris, Vincent Gotz, Winslow Klaskala, Clinical experience with nonstandard doses ofinterferon alfa-2b and ribavirin in the treatment of chronic hepatitis C infection: A retrospective analysis, Current Therapeutic Research, 2005, 66, 5, 433

    CrossRef

55. 55
    Vijayan Balan, David Schwartz, George Y. Wu, Andrew J. Muir, Reem Ghalib, John Jackson, Emmet B. Keeffe, Lorenzo Rossaro, Alfreda Burnett, Betty L. Goon, Peter J. Bowers, Gerhard J. Leitz, Erythropoietic Response to Anemia in Chronic Hepatitis C Patients Receiving Combination Pegylated Interferon/Ribavirin, The American Journal of Gastroenterology, 2005, 100, 2, 299

    CrossRef

56. 56
    T. Barry Kelleher, Nezam H. Afdhal, Maintenance therapy for chronic hepatitis C, Current Gastroenterology Reports, 2005, 7, 1, 50

    CrossRef

57. 57
    Alan S. Perelson, Eva Herrmann, Florence Micol, Stefan Zeuzem, New kinetic models for the hepatitis C virus, Hepatology, 2005, 42, 4

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(135K)
    • References
58. 58
    Abdel-Rahman El-Zayadi, Mohy Attia, Hanaa M. Badran, Ahmed El-Tawil, Khaled Zalata, Eman Barakat, Osaima Selim, Adham El-Nakeeb, Ahmed Saied, Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy, Liver International, 2005, 25, 4

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(294K)
    • References
59. 59
    Gillian M Keating, Greg L Plosker, Peginterferon ??-2a (40KD) Plus Ribavirin, Drugs, 2005, 65, 4, 521

    CrossRef

60. 60
    Ivanka Zic, Peginterferon Alpha/Ribavirin Combination Therapy for the Treatment of Hepatitis C Infection, Gastroenterology Nursing, 2005, 28, 4, 317

    CrossRef

61. 61
    Michael J Grace, David L Cutler, Ronald W Bordens, Pegylated IFNs for chronic hepatitis C: an update, Expert Opinion on Drug Delivery, 2005, 2, 2, 219

    CrossRef

62. 62
    R. Moreno-Otero, Therapeutic modalities in hepatitis C: challenges and development, Journal of Viral Hepatitis, 2005, 12, 1

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(98K)
    • References
63. 63
    T. Galpérine, C. Merle, P. de Truchis, L. Bernard, C. Perronne, Tolérance et interactions médicamenteuses des traitements anti-VIH et anti-VHC, Médecine et Maladies Infectieuses, 2005, 35, 3, 135

    CrossRef

64. 64
    Michael P Manns, Adherence to combination therapy: influence on sustained virologic response and economic impact, Gastroenterology Clinics of North America, 2004, 33, 1, 11

    CrossRef

65. 65
    Sangik Oh, Nezam H. Afdhal, Antiviral therapy for treatment naı̈ve patients with hepatitis C virus, Gastroenterology Clinics of North America, 2004, 33, 3, 497

    CrossRef

66. 66
    M. S. Sulkowski, R. Wasserman, L. Brooks, L. Ball, R. Gish, Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection, Journal of Viral Hepatitis, 2004, 11, 3

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(93K)
    • References
67. 67
    Nezam H. Afdhal, Douglas T. Dieterich, Paul J. Pockros, Eugene R. Schiff, Mitchell L. Shiffman, Mark S. Sulkowski, Teresa Wright, Zobair Younossi, Betty L. Goon, K.Linda Tang, Peter J. Bowers, Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medicine, Houston, Texas; Greg Everson, M.D., University of Colorado Health Sciences Center, Denver, Colorado; Michael Fried, M.D., University of North Carolina, Chapel Hill, North Carolina; Robert Gish, M.D., California Pacific Medical Center, San Francisco, California; Ira Jacobson, M.D., Weill Medical College of Cornell University, New York, New York; John W. King, LSU Health Sciences Center, Shreveport, LA; Raymond Koff, M.D., University of Massachusetts Memorial Health Care, Worcester, Massachusetts; William Lee, M.D., University of Texas Southwestern Medical Center, Dallas, Texas; Mark A. Levstik, M.D., The University of Tennessee, Memphis, Tennessee; John G. McHutchison, M.D., Scripps Clinic, La Jolla, California; Marion Peters, M.D., University of California San Francisco, San Francisco, California; Kenneth Sherman, M.D., Ph.D., University of Cincinnati College of Medicine, Cincinnati, Ohio; Coleman Smith, M.D., Minnesota Clinical Research Center, St. Paul, MN; Ronald Wasserman, M.D., Hepatitis Resource Center, Walnut Creek, California., Gastroenterology, 2004, 126, 5, 1302

    CrossRef

68. 68
    Narendra M. Dixit, Jennifer E. Layden-Almer, Thomas J. Layden, Alan S. Perelson, Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature, 2004, 432, 7019, 922

    CrossRef

69. 69
    S.James Matthews, Christopher McCoy, Peginterferon alfa-2a: A review of approved and investigational uses, Clinical Therapeutics, 2004, 26, 7, 991

    CrossRef

70. 70
    Nezam H. Afdhal, Role of epoetin alfa in maintaining ribavirin dose, Gastroenterology Clinics of North America, 2004, 33, 1, 25

    CrossRef

71. 71
    Robert G. Gish, Treating hepatitis C: the state of the art, Gastroenterology Clinics of North America, 2004, 33, 1, 1

    CrossRef

72. 72
    Hector Rodriguez-Luna, Amer Khatib, Pratima Sharma, Giovanni De Petris, James W. Williams, Jose Ortiz, Kathleen Hansen, David Mulligan, Adyr Moss, David D. Douglas, Vijayan Balan, Jorge Rakela, Hugo E. Vargas, Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1, Transplantation, 2004, 77, 2, 190

    CrossRef

73. 73
    Furqaan Ahmed, Ira M. Jacobson, Treatment of relapsers after combination therapy for chronic hepatitis C, Gastroenterology Clinics of North America, 2004, 33, 3, 513

    CrossRef

74. 74
    Kuo-Hsiung Shu, Joung-Liang Lan, Ming-Ju Wu, Chi-Hung Cheng, Chen-Hsu Chen, Wen-Chin Lee, Horng-Rong Chang, Jong-Da Lian, ULTRALOW-DOSE ALPHA-INTERFERON PLUS RIBAVIRIN FOR THE TREATMENT OF ACTIVE HEPATITIS C IN RENAL TRANSPLANT RECIPIENTS, Transplantation, 2004, 77, 12, 1894

    CrossRef

75. 75
    Eva Herrmann, Stefan Zeuzem, Update on viral kinetics and hcv antiviral therapy, Current Hepatitis Reports, 2004, 3, 1, 5

    CrossRef

76. 76
    Mark A. Virtue, Julie K. Furne, Samuel B. Ho, Michael D. Levitt, Use of alveolar carbon monoxide to measure the effect of ribavirin on red blood cell survival, American Journal of Hematology, 2004, 76, 2

    Direct Link:

    • Abstract
    • PDF(100K)
    • References
77. 77
    Victor E Buckwold, Brigitte E Beer, Ruben O Donis, Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents, Antiviral Research, 2003, 60, 1, 1

    CrossRef

78. 78
    Federica Benini, Luciana Distefano, Ornella Baisini, Marie Graciella Pigozzi, Alberto Lanzini, Efficacy and Tolerability of Combination Therapy with Interferon-Alfa Plus Ribavirin in Patients with Chronic Hepatitis C Virus Infection: A Single-Center Study in Relapsers and Nonresponders to Previous Treatment with High-Dose Interferon-Alfa Monotherapy, Current Therapeutic Research, 2003, 64, 3, 140

    CrossRef

79. 79
    Douglas H Osato, Conrad C Huang, Michiko Kawamoto, Susan J Johns, Doug Stryke, Joanne Wang, Thomas E Ferrin, Ira Herskowitz, Kathleen M Giacomini, Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1, Pharmacogenetics, 2003, 13, 5, 297

    CrossRef

80. 80
    Omar I. Massoud, Wael I. Yousef, Kevin D. Mullen, Hemoglobinuria With Ribavirin Treatment, Journal of Clinical Gastroenterology, 2003, 36, 4, 367

    CrossRef

81. 81
    Kung-Chia Young, Karen L. Lindsay, Ki-Jeong Lee, Wen-Chun Liu, Jian-Wen He, Susan L. Milstein, Michael M. C. Lai, Identification of a Ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy, Hepatology, 2003, 38, 4

    Direct Link:

    • Abstract
    • PDF(1055K)
    • References
82. 82
    Douglas T. Dieterich, Ronald Wasserman, Norbert Brau, Tarek I. Hassanein, Edmund J. Bini, Peter J. Bowers, Mark S. Sulkowski, Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa, The American Journal of Gastroenterology, 2003, 98, 11, 2491

    CrossRef

83. 83
    Gillian M Keating, Monique P Curran, Peginterferon-??-2a (40kD) Plus Ribavirin, Drugs, 2003, 63, 7, 701

    CrossRef

84. 84
    Wolfgang Vogel, Peginterferon-α2a(40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection, Expert Review of Anti-infective Therapy, 2003, 1, 3, 423

    CrossRef

85. 85
    Volker Meier, Erik Bürger, Sabine Mihm, Bernhard Saile, Giuliano Ramadori, Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: Possible explanation for therapeutic efficacy in patients with chronic HCV infection, Journal of Medical Virology, 2003, 69, 1

    Direct Link:

    • Abstract
    • PDF(265K)
    • References
86. 86
    Zhi Hong, The role of Ribavirin-induced mutagenesis in HCV therapy: A concept or a fact?, Hepatology, 2003, 38, 4

    Direct Link:

    • Abstract
    • PDF(411K)
    • References
87. 87
    P. J. Pockros, R. Reindollar, J. McHutchinson, R. Reddy, T. Wright, D.G. Boyd, L.B. Wilkes, The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients, Journal of Viral Hepatitis, 2003, 10, 1

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(85K)
    • References
88. 88
    Gary L. Davis, Treatment of chronic hepatitis C: Improved combination therapy, Current Hepatitis Reports, 2003, 2, 1, 40

    CrossRef

89. 89
    P.-N. Cheng, N.-H. Chow, S.-C. Hu, K.-C. Young, C.-Y. Chen, C.-M. Jen, T.-T. Chang, Clinical comparison of high-dose interferon-α2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C, Digestive and Liver Disease, 2002, 34, 12, 851

    CrossRef

90. 90
    Amy W. Poret, Ronald J. Ozminkowski, Ron Goetzel, Jaime E. Pew, Jean Balent, Cost Burden of Illness for Hepatitis C Patients with Employer-Sponsored Health Insurance, Disease Management, 2002, 5, 2, 95

    CrossRef

91. 91
    Paul J Pockros, Developments in the treatment of chronic hepatitis C, Expert Opinion on Investigational Drugs, 2002, 11, 4, 515

    CrossRef

92. 92
    Brent D Lemberg, Thomas A Shaw-Stiffel, Hepatic disease in injection drug users, Infectious Disease Clinics of North America, 2002, 16, 3, 667

    CrossRef

93. 93
    Stephen Pianko, John G. McHutchison, Stuart C. Gordon, Shanon Heaton, Zachary D. Goodman, Keyur Patel, Cherise M. Cortese, Elizabeth M. Brunt, Bruce R. Bacon, Lawrence M. Blatt, Hepatic Iron Concentration Does Not Influence Response to Therapy with Interferon Plus Ribavirin in Chronic HCV Infection, Journal of Interferon & Cytokine Research, 2002, 22, 4, 483

    CrossRef

94. 94
    Rafael Quadri, Emiliano Giostra, Tania Roskams, Jean-Michel Pawlotsky, Gilles Mentha, Laura Rubbia-Brandt, Luc Perrin, Antoine Hadengue, Francesco Negro, IMMUNOLOGICAL AND VIROLOGICAL EFFECTS OF RIBAVIRIN IN HEPATITIS C AFTER LIVER TRANSPLANTATION1, Transplantation, 2002, 73, 3, 373

    CrossRef

95. 95
    Lesley J. Scott, Caroline M. Perry, Interferon-??-2b Plus Ribavirin, Drugs, 2002, 62, 3, 507

    CrossRef

96. 96
    Richard A. Willson, Nephrotoxicity of Interferon Alfa–Ribavirin Therapy for Chronic Hepatitis C, Journal of Clinical Gastroenterology, 2002, 35, 1, 89

    CrossRef

97. 97
    V. Carreño, Present treatment expectations and risks of chronic hepatitis C, Clinical Microbiology and Infection, 2002, 8, 2

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(63K)
    • References
98. 98
    Serguey Ouzounov, Anand Mehta, Raymond A Dwek, Timothy M Block, Robert Jordan, The combination of interferon α-2b and n-butyl deoxynojirimycin has a greater than additive antiviral effect upon production of infectious bovine viral diarrhea virus (BVDV) in vitro: implications for hepatitis C virus (HCV) therapy, Antiviral Research, 2002, 55, 3, 425

    CrossRef

99. 99
    R. Cozzolongo, R. Cuppone, V. Giannuzzi, L. Amati, L. Caradonna, V. Tamborrino, E. Jirillo, O. G. Manghisi, Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon, Alimentary Pharmacology & Therapeutics, 2001, 15, 1

    Direct Link:

    • Abstract
    • Full Article (HTML)
    • PDF(74K)
    • References
100. 100
     Javaid A. Shad, John G. McHutchison, CURRENT AND FUTURE THERAPIES OF HEPATITIS C, Clinics in Liver Disease, 2001, 5, 2, 335

     CrossRef

101. 101
     P. Andreone, C. Cursaro, A. Gramenzi, M. Margotti, E. Ferri, S. Talarico, M. Biselli, F. Felline, C. Tuthill, E. Martins, G. Gasbarrini, M. Bernardi, In vitro effect of thymosin-α1 and interferon-α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C, Journal of Viral Hepatitis, 2001, 8, 3

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(314K)
     • References
102. 102
     Mitchell L. Shiffman, MANAGEMENT OF INTERFERON THERAPY NONRESPONDERS, Clinics in Liver Disease, 2001, 5, 4, 1025

     CrossRef

103. 103
     E. Beth Devine, Kris V. Kowdley, David L. Veenstra, Sean D. Sullivan, Management Strategies for Ribavirin-Induced Hemolytic Anemia in the Treatment of Hepatitis C: Clinical and Economic Implications, Value in Health, 2001, 4, 5

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(113K)
     • References
104. 104
     Marlene Modi, Nancy Martin, Jenny E Heathcote, Keith Nieforth, Stefan Zeuzem, Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy, Expert Opinion on Investigational Drugs, 2001, 10, 12, 2201

     CrossRef

105. 105
     J. G. McHutchison, J. A. Shad, S. C. Gordon, T. R. Morgan, M.-H. Ling, J.-J. Garaud, J. K. Albrecht, J. L. Dienstag, Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy, Journal of Viral Hepatitis, 2001, 8, 6

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(103K)
     • References
106. 106
     Stefan Zeuzem, THE KINETICS OF HEPATITIS C VIRUS INFECTION, Clinics in Liver Disease, 2001, 5, 4, 917

     CrossRef

107. 107
     Anne Gervais, Nathalie Boyer, Patrick Marcellin, Tolerability of Treatments for Viral Hepatitis, Drug Safety, 2001, 24, 5, 375

     CrossRef

108. 108
     Richard S. Ferri, Anthony Adinolfi, Allen J. Orsi, David J. Sterken, Jeannie C. Keruly, Sheila Davis, Richard C. MacIntyre, Treatment of Anemia in Patients With HIV Infection, Part 1: The Need for Adequate Guidelines, Journal of the Association of Nurses in AIDS care, 2001, 12, 6, 39

     CrossRef

109. 109
     Laura Benson, Alice Birkel, Linda Caldwell, Valerie Stafford-Fox, Beverley Casarico, Advances in the Treatment of Hepatitis C: Combination Antiviral Therapy With Interferon alfa-2b and Ribavirin, Journal of the American Academy of Nurse Practitioners, 2000, 12, 9

     Direct Link:

     • Abstract
     • PDF(322K)
     • References
110. 110
     Anuchit Chutaputti, Adverse effects and other safety aspects of the hepatitis C antivirals, Journal of Gastroenterology and Hepatology, 2000, 15,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • References
111. 111
     Mitchell L. Shiffman, Scott B. Verbeke, Pamela M. Kimball, Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes, Antiviral Research, 2000, 48, 2, 91

     CrossRef

112. 112
     Gary L. Davis, Current therapy for chronic hepatitis C, Gastroenterology, 2000, 118, 2, S104

     CrossRef

113. 113
     Ming-Yang Lai, Firstline treatment for hepatitis C: combination interferon/ribavirin versus interferon monotherapy, Journal of Gastroenterology and Hepatology, 2000, 15,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • References
114. 114
     Catherine Petruff Cheney, Sanjiv Chopra, Camilla Graham, HEPATITIS C, Infectious Disease Clinics of North America, 2000, 14, 3, 633

     CrossRef

115. 115
     Matthew E. Cramp, Siegbert Rossol, Shilpa Chokshi, Patrizia Carucci, Roger Williams, Nikolai V. Naoumov, Hepatitis C virus–specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C, Gastroenterology, 2000, 118, 2, 346

     CrossRef

116. 116
     M. Isabel Fiel, MD, Thomas D. Schiano, MD, Maria Guido, MD, Swan N. Thung, MD, Karen L. Lindsay, MD, Gary L. Davis, MD, James H. Lewis, MD, Leonard B. Seeff, MD, Henry C. Bodenheimer, MD, Increased Hepatic Iron Deposition Resulting From Treatment of Chronic Hepatitis C With Ribavirin, American Journal of Clinical Pathology, 2000, 113, 1, 35

     CrossRef

117. 117
     S. Tripi, G. Di Gaetano, M. Soresi, F. Cartabellotta, R. Vassallo, A. Carroccio, G. Anastasi, G. Montalto, Interferon-?? Alone versus Interferon-?? plus Ribavirin in Patients with Chronic Hepatitis C Not Responding to Previous Interferon-?? Treatment, BioDrugs, 2000, 13, 4, 299

     CrossRef

118. 118
     Berwyn E. Clarke, New drugs for hepatitis C virus (HCV), Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 293

     CrossRef

119. 119
     Edward Gane, Pre- and post-transplant treatment of hepatitis C, Journal of Gastroenterology and Hepatology, 2000, 15,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • References
120. 120
     J. Enríquez, A. Gallego, X. Torras, T. Pérez-Olmeda, M. Diago, V. Soriano, M.-S. Luján, J. García-Samaniego, Retreatment for 24 vs 48 weeks with interferon-α2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone , Journal of Viral Hepatitis, 2000, 7, 6

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(66K)
     • References
121. 121
     G.R Foster, H.C Thomas, Therapeutic options for HCV—management of the infected individual, Best Practice & Research Clinical Gastroenterology, 2000, 14, 2, 255

     CrossRef

122. 122
     Daniel A. Carrasco, Catherine Newman, Stephen K. Tyring, Treatment of viral hepatitis, Dermatologic Therapy, 2000, 13, 3

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(170K)
     • References
123. 123
     Arie Regev, Eugene R. Schiff, VIRAL HEPATITIS A, B, AND C, Clinics in Liver Disease, 2000, 4, 1, 47

     CrossRef

124. 124
     Lisa Nyberg, Janice Albrecht, Paul Glue, Gianluigi Gianelli, Demetris Zambas, Michael Elliot, A. Conrad, John McHutchison, Changes in Serum Hepatitis C Virus RNA in Interferon Nonresponders Retreated With Interferon Plus Ribavirin, Journal of Clinical Gastroenterology, 1999, 28, 4, 313

     CrossRef

125. 125
     Gary L. Davis, COMBINATION TREATMENT WITH INTERFERON AND RIBAVIRIN FOR CHRONIC HEPATITIS C, Clinics in Liver Disease, 1999, 3, 4, 811

     CrossRef

126. 126
     Sammy Saab, Paul Martin, Hemolytic Anemia and the Treatment of Chronic Hepatitis C, Journal of Clinical Gastroenterology, 1999, 28, 4, 289

     CrossRef

127. 127
     Vincent Soriano, Rafael Rodríguez-Rosado, Javier García-Samaniego, Management of chronic hepatitis C in HIV-infected patients, AIDS, 1999, 13, 5, 539

     CrossRef

128. 128
     M. S. Cattral, A. W. Hemming, I. R. Wanless, H. Al Ashgar, M. Krajden, L. Lilly, P. D. Greig, G. A. Levy, OUTCOME OF LONG-TERM RIBAVIRIN THERAPY FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION, Transplantation, 1999, 67, 9, 1277

     CrossRef

129. 129
     Danuta Stryjek-Kaminska, Falk Ochsendorf, Claudia Roder, Manfred Wolter, Stefan Zeuzem, Photoallergic skin reaction to ribavirin, The American Journal of Gastroenterology, 1999, 94, 6, 1686

     CrossRef

130. 130
     Regino P González-Peralta, George J Galasso, Thierry Poynard, Solko Schalm, Howard C Thomas, Teresa L Wright, Summary of the first international symposium on viral hepatitis, Antiviral Research, 1999, 42, 2, 77

     CrossRef

131. 131
     C. Silvain, Traitements antiviraux de l’infection par le virus de l’hépatite C, La Revue de Médecine Interne, 1999, 20, 331s

     CrossRef

132. 132
     Gary L. Davis, Treatment of chronic hepatitis C: Impact of combination therapy, Current Gastroenterology Reports, 1999, 1, 1, 9

     CrossRef

133. 133
     T. Jake Liang, Combination Therapy for Hepatitis C Infection, New England Journal of Medicine, 1998, 339, 21, 1549

     CrossRef

134. 134
     John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff, Mitchell L. Shiffman, William M. Lee, Vinod K. Rustgi, Zachary D. Goodman, Mei-Hsiu Ling, Susannah Cort, Janice K. Albrecht, Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C, New England Journal of Medicine, 1998, 339, 21, 1485

     CrossRef

135. 135
     Gary L. Davis, Rafael Esteban-Mur, Vinod Rustgi, John Hoefs, Stuart C. Gordon, Christian Trepo, Mitchell L. Shiffman, Stefan Zeuzem, Antonio Craxi, Mei-Hsiu Ling, Janice Albrecht, Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C, New England Journal of Medicine, 1998, 339, 21, 1493

     CrossRef

136. 136
     Moreno-Monteagudo, Fernández-Bermejo, García-Buey, Sanz, Iacono, García-Monzón, Borque, Moreno-Otero, Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy, Alimentary Pharmacology & Therapeutics, 1998, 12, 8

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(159K)
     • References
137. 137
     Thierry Poynard, Patrick Marcellin, Samuel S Lee, Christian Niederau, Gerald S Minuk, Gaetano Ideo, Vincent Bain, Jenny Heathcote, Stefan Zeuzem, Christian Trepo, Janice Albrecht, Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, The Lancet, 1998, 352, 9138, 1426

     CrossRef

138. 138
     F. Zoulim, J. Haem, S. Si Ahmed, P. Chossegros, F. Habersetzer, M. Chevallier, F. Bailly, C. Trépo, Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients, Journal of Viral Hepatitis, 1998, 5, 3

     Direct Link:

     • Abstract
     • PDF(141K)
139. 139
     C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, G. M. DUSHEIKO, Therapy for chronic hepatitis B and C infection in haemophilia, Haemophilia, 1998, 4, 4

     Direct Link:

     • Abstract
     • PDF(1535K)
     • References
140. 140
     G Götz, M.R Schön, A Haefker, R Neuhaus, T Berg, U Hopf, P Neuhaus, Treatment of recurrent hepatitis c virus infection after liver transplantation with interferon and ribavirin, Transplantation Proceedings, 1998, 30, 5, 2104

     CrossRef

141. 141
     Mitchell L. Shiffman, Cytopenias: How they Limit Therapy and Potential Correction,

     Direct Link:

     • Summary
     • PDF(119K)
     • References
142. 142
     Jama M. Darling, Stanley M. Lemon, Michael W. Fried, Hepatitis C,

     Direct Link:

     • Summary
     • PDF(3487K)
     • References
143. 143
     Jesper Brok, Lise Lotte Gluud, Christian Gluud, Ribavirin monotherapy for chronic hepatitis C, The Cochrane Library,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(634K)
     • References
144. 144
     Jesper Brok, Lise Lotte Gluud, Christian Gluud, Ribavirin monotherapy for chronic hepatitis C, The Cochrane Library,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(469K)
     • References
145. 145
     Jesper Brok, Lise Lotte Gluud, Christian Gluud, Ribavirin plus interferon versus interferon for chronic hepatitis C, The Cochrane Library,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(1050K)
     • References
146. 146
     Jesper Brok, Lise Lotte Gluud, Christian Gluud, Ribavirin plus interferon versus interferon for chronic hepatitis C, The Cochrane Library,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(1376K)
     • References
147. 147
     Lise Lotte Gluud, Kim Krogsgaard, Christian Gluud, Ribavirin with or without alpha interferon for chronic hepatitis C, The Cochrane Library,

     Direct Link:

     • Abstract
     • Full Article (HTML)
     • PDF(54K)
     • References
148. 148
     Ed Gane, Treatment of Recurrent Hepatitis C Following Liver Transplantation,

     Direct Link:

     • Summary
     • PDF(144K)
     • References